Is this a measure (or updated version of a measure previously submitted to NQF and given an NQF#?

 Yes NQF 2082 HIV viral load suppression

Several conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards. If any of the conditions are not met, the measure will not be accepted for consideration.

Do you agree to these conditions?

X I have read and accept the conditions as specified above \*

Descriptive Information

De.1. Measure Type health outcome

[De.2. Measure Title *‐* HIV viral suppression](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/what_good_looks_like.aspx)

De.3. Brief description of measure (*including type of score, measure focus, target population, timeframe, e.g.,* *Percentage of adult patients aged 18‐75 years receiving one or more HbA1c tests per year*)

Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year

De.4. IF PAIRED/GROUPED, what is the reason this measure must be reported with other measures to appropriately interpret results? N/A

S.1. Measure‐specific Web Page

Information about the measure can be found at Health Resources and Services Administration Ryan White and Global HIV/AIDS Programs website http://hab.hrsa.gov/clinical-quality-management/performance-measure-portfolio

S.2a. If this is an eMeasure,

We will submit HIV viral suppression as both a chart abstracted measure and an e-measure. This form is for the chart abstracted measure.

S.2b. Data Dictionary, Code Table, or Value Sets *(and risk model codes and coefficients when applicable) must* *be attached. (Excel or csv file in the suggested format preferred ‐ if not, contact staff. Provide descriptors for any codes. Use one file with multiple worksheets as needed.)*

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables Used** | **Variable Name Created** | **Logic** | **Notes** |
| Firstambulatorycaredate;  HIV(AIDS)diagnosisyear | step\_1 | case when month(firstambulatorycaredate) > 3   and &var = &year   and euci42 not in (select distinct euci42 from raw&year..rsrambul group by euci42 having min(datepart(servicedate)) <"01APR&YY"d )  then 0 else 1 end | This logic excludes individuals who are explicitly diagnosed during the measurement year and receive their first service with any provider after March. All others are included in the denominator. |
| servicecategoryid | core\_medical | max(case when servicecategoryid in (8,10,11,13,14,15,16,17,18,19) then 1 else 0 end) where euci42 corresponds to step\_1 == 1 | This is conditioning on receiving ANY OAMC service, not necessarily receiving an OAMC service from a specific provider |
| count | viral\_load | max(case when count>=0 then 1 else 0 end), conditional on core\_medical = 1 | If a person ever has a viral load test during the year and has a core medical service then will be in this group |
| count | viral\_suppression | max(case when count>0 and count < 200 then 1 else 0 end) , conditional on Viral\_load = 1 |  |

S.3.1. For maintenance of endorsement: Are there changes to the specifications since the last updates/submission. If yes, update the specifications for S1‐2 and S4‐22 and explain reasons for the changes in S3.2.

 No

S.3.2. For maintenance of endorsement, please briefly describe any important changes to the measure specifications since last measure update and explain the reasons. None

S.4. Numerator Statement

Number of patients in the denominator with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year.

*IF an OUTCOME MEASURE, state the outcome being measured. Calculation of the risk‐adjusted outcome should be described in the calculation algorithm (S.14).*

The outcome being measured is HIV viral suppression. This measure does not contain risk adjustment.

S.5. Numerator Details

To be included in the numerator, patients had a HIV viral load less than 200 copies/mL at the last HIV viral load test during the measurement year.

*IF an OUTCOME MEASURE, describe how the observed outcome is identified/counted. Calculation of the risk‐ adjusted outcome should be described in the calculation algorithm (S.14).*

A viral load is a laboratory test that quantified the number of HIV copies in a milliliter of blood. Clinicians order viral load test to be performed on patients’ blood specimens.

S.6. Denominator Statement

Number of patients, regardless of age, with a diagnosis of HIV with at least one medical visit in the measurement year.

*IF an OUTCOME MEASURE, state the target population for the outcome. Calculation of the risk‐adjusted outcome should be described in the calculation algorithm (S.14).*

The target population for this measure is all people living with HIV. This measure does not contain risk adjustment.

S.7. Denominator Details

To be included in the denominator, patients must meet all of the following conditions/events:

1. Patients of any age during the measurement year
2. Patients diagnosed with HIV during the first 3 months of the measurement year or prior to the measurement year
3. Patients who had at least one medical visit during the measurement year

*IF an OUTCOME MEASURE, describe how the target population is identified. Calculation of the risk‐adjusted outcome should be described in the calculation algorithm (S.14).*

The target population is identified by selecting patients based on their diagnosis with HIV.This measure does not contain risk adjustment.

S.8. Denominator Exclusions

There are no patient exclusions.

S.9. Denominator Exclusion Details

There are no patient exclusions.

S.10. Stratification Information N/A

S.11. Risk Adjustment Type (Select type. Provide specifications for risk stratification in measure testing attachment) N/A

S.12. Type of score: Percentage

S.13. Interpretation of Score

Better quality is associated with a higher score.

S.14. Calculation Algorithm/Measure Logic

1. Identify the individuals who satisfy all specific criteria for inclusion in the denominator: 1.) diagnosed with a HIV during the

first 3 months of the measurement year or prior to the measurement year; and 2.) had at least one medical visit during the

measurement year. The individuals who met these criteria are the denominator population.

1. Identify the individuals from the denominator population who meet the criterion for inclusion in the numerator: had a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year.
2. Calculate the percentage by dividing the numerator population by the denominator population and multiply by 100.

Also illustrated in the diagram below.



S.15. Sampling *(If measure is based on a sample, provide instructions for obtaining the sample and guidance on* *minimum sample size.)*

This measure does not sample.

S.16. Survey/Patient‐reported data *(If measure is based on a survey or instrument, provide instructions for data* *collection and guidance on minimum response rate.)*

This measure is not based on a survey or instrument.

S.17. Data Source *(Check ONLY the sources for which the measure is SPECIFIED AND TESTED).* *If other, please describe in S.18.*

Paper Records: As previously stated, this measure will be submitted as a chart abstracted measure and an e-measure. This submission is for the chart abstracted measure.

S.18. Data Source or Collection Instrument

Electronic or paper records

S.19. Data Source or Collection Instrument *(available at measure‐specific Web page URL identified in S.1 OR in* *attached appendix)*

No data collection instrument provided.

S.20. Level of Analysis *(Check ONLY the levels of analysis for which the measure is SPECIFIED AND TESTED)*

Facility

S.21. Care Setting *(Check ONLY the settings for which the measure is SPECIFIED AND TESTED)*

Clinician Office/Clinic

S.22. COMPOSITE Performance Measure ‐ This is not a composite measure.

Importance

Evidence ([Measure evaluation criterion 1a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#1a))

1a. Attach evidence submission form ([Click here to download Evidence Submission Form Template](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/NQF_evidence_attachment_FINAL_2016.aspx))

1a.1. For maintenance of endorsement:

Is there new evidence about the measure since the last update/submission?

Yes

Performance Gap ‐ Opportunity for Improvement ([Measure evaluation criterion 1b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#1b))

1b.1. Briefly explain the rationale for this measure

Sustained viral load suppression is directly related to reduction in disease progression, morbidity, and mortality; and to reduction in potential for transmission of infection. Among persons in care, sustained viral load suppression represents the cumulative effect of prescribed therapy, ongoing monitoring, and patient adherence. The proposed measure will direct providers’ attention and quality improvement efforts towards this important outcome.

In 2011, the HIV community saw the emergence of the HIV care continuum.  This simple model outlines the sequential steps of medical care that people living with HIV go through from initial diagnosis to achieving the goal of viral suppression.  The steps include diagnosis, linkage to care, retention in care, receipt of HIV antiretroviral therapy and viral suppression.  This model has been incorporated into the National HIV/AIDS Strategy as it has focused all HIV prevention, care, and treatment efforts in the United States.  As outlined in the model, all though there are five different steps, each step is dependent upon each other.   For instance, you cannot become virally suppressed if you are not receiving HIV antiretroviral therapy or retained in medical care.

The most recent nationwide data from CDC dated 2014 estimates that although 86% of people living with HIV have been diagnosed, only 40% are engaged in care, 37% have been prescribed HIV antiretroviral therapy, and 30% have achieved viral suppression.

Right now, we are at a very special time and place.  Many states and large metropolitan areas across the United States have developed plans to end the HIV epidemic in the communities.  These jurisdictions have used the HIV care continuum and its steps as the framework by which they have developed their plans.

In closing, the measures we have put forth are in alignment with the HIV care continuum.  We see these measures as a suite – each important as individual measures, but work together as a suite to improve health outcomes for people living with HIV in the United States.

1b.2. Provide performance scores on the measure as specified

Provider-level performance scores for viral load suppression for 2014 are presented below. Summary statistics (mean, std dev, min, max, interquartile range, scores by decile) for viral load suppression across all providers are presented separately. Data for years 2010-2013 are available upon request and were omitted due to space constraints.

Provider-level viral suppression performance scores, 2014

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Site/provider ID | Total N | Patients w/ ≥1 medical visits during measurement year (n) | Patients w/ viral load test during measurement year | Number of patients with viral suppression (a) | % of patients with viral suppression (a/n) |
| **OVERALL** | **316087** | **316087** | **293237** | **255342** | **80.8%** |
| 55 | 417 | 417 | 288 | 282 | 67.6% |
| 63 | 24 | 24 | 18 | 10 | 41.7% |
| 82 | 93 | 93 | 91 | 83 | 90.0% |
| 88 | 1052 | 1052 | 970 | 886 | 90.0% |
| 96 | 613 | 613 | 480 | 421 | 68.7% |
| 101 | 140 | 140 | 137 | 119 | 90.0% |
| 105 | 145 | 145 | 135 | 120 | 90.0% |
| 112 | 196 | 196 | 194 | 181 | 92.3% |
| 113 | 248 | 248 | 248 | 237 | 95.6% |
| 117 | 1197 | 1197 | 1141 | 1060 | 90.0% |
| 118 | 331 | 331 | 330 | 312 | 94.3% |
| 120 | 153 | 153 | 148 | 129 | 90.0% |
| 123 | 459 | 459 | 454 | 397 | 90.0% |
| 124 | 212 | 212 | 208 | 156 | 73.6% |
| 127 | 288 | 288 | 283 | 200 | 69.4% |
| 128 | 484 | 484 | 476 | 411 | 90.0% |
| 133 | 2437 | 2437 | 2078 | 1823 | 74.8% |
| 135 | 140 | 140 | 138 | 131 | 93.6% |
| 138 | 44 | 44 | 44 | 31 | 70.5% |
| 140 | 11 | 11 | 11 | 11 | 100.0% |
| 141 | 216 | 216 | 163 | 146 | 67.6% |
| 143 | 124 | 124 | 121 | 113 | 91.1% |
| 144 | 337 | 337 | 324 | 288 | 90.0% |
| 147 | 139 | 139 | 136 | 100 | 71.9% |
| 148 | 49 | 49 | 49 | 32 | 65.3% |
| 149 | 115 | 115 | 110 | 103 | 90.0% |
| 154 | 588 | 588 | 578 | 547 | 93.0% |
| 155 | 23 | 23 | 23 | 20 | 90.0% |
| 156 | 46 | 46 | 30 | 24 | 52.2% |
| 158 | 134 | 134 | 134 | 122 | 91.0% |
| 159 | 218 | 218 | 213 | 195 | 90.0% |
| 160 | 90 | 90 | 83 | 68 | 75.6% |
| 164 | 71 | 71 | 60 | 55 | 77.5% |
| 168 | 766 | 766 | 735 | 690 | 90.1% |
| 169 | 144 | 144 | 130 | 126 | 90.0% |
| 170 | 259 | 259 | 255 | 235 | 90.7% |
| 171 | 280 | 280 | 257 | 231 | 90.0% |
| 172 | 289 | 289 | 288 | 280 | 96.9% |
| 173 | 154 | 154 | 149 | 125 | 90.0% |
| 174 | 346 | 346 | 342 | 321 | 92.8% |
| 175 | 157 | 157 | 151 | 135 | 90.0% |
| 176 | 1909 | 1909 | 1788 | 1672 | 90.0% |
| 177 | 63 | 63 | 58 | 53 | 90.0% |
| 178 | 1541 | 1541 | 1435 | 1331 | 90.0% |
| 179 | 81 | 81 | 81 | 73 | 90.1% |
| 181 | 518 | 518 | 501 | 444 | 90.0% |
| 182 | 919 | 919 | 511 | 463 | 50.4% |
| 183 | 478 | 478 | 457 | 423 | 90.0% |
| 184 | 369 | 369 | 367 | 345 | 93.5% |
| 186 | 101 | 101 | 101 | 96 | 95.0% |
| 187 | 404 | 404 | 398 | 366 | 90.6% |
| 188 | 471 | 471 | 467 | 359 | 76.2% |
| 191 | 364 | 364 | 352 | 330 | 90.7% |
| 192 | 560 | 560 | 492 | 430 | 76.8% |
| 194 | 228 | 228 | 219 | 187 | 90.0% |
| 196 | 1160 | 1160 | 1123 | 1018 | 90.0% |
| 197 | 1145 | 1145 | 1092 | 960 | 90.0% |
| 199 | 514 | 514 | 505 | 398 | 77.4% |
| 201 | 3059 | 3059 | 3028 | 2610 | 90.0% |
| 203 | 793 | 793 | 774 | 681 | 90.0% |
| 205 | 12 | 12 | 11 | 8 | 66.7% |
| 207 | 329 | 329 | 322 | 295 | 90.0% |
| 209 | 192 | 192 | 187 | 146 | 76.0% |
| 210 | 120 | 120 | 113 | 92 | 76.7% |
| 211 | 458 | 458 | 442 | 371 | 90.0% |
| 212 | 234 | 234 | 231 | 192 | 90.0% |
| 213 | 1312 | 1312 | 1283 | 1009 | 76.9% |
| 214 | 694 | 694 | 694 | 626 | 90.2% |
| 215 | 347 | 347 | 343 | 284 | 90.0% |
| 216 | 495 | 495 | 495 | 422 | 90.0% |
| 217 | 247 | 247 | 244 | 213 | 90.0% |
| 220 | 298 | 298 | 297 | 269 | 90.3% |
| 221 | 186 | 186 | 179 | 156 | 90.0% |
| 222 | 351 | 351 | 332 | 303 | 90.0% |
| 223 | 1674 | 1674 | 1485 | 1318 | 78.7% |
| 224 | 534 | 534 | 521 | 481 | 90.1% |
| 225 | 1947 | 1947 | 1833 | 1627 | 90.0% |
| 227 | 1004 | 1004 | 941 | 813 | 90.0% |
| 228 | 187 | 187 | 185 | 163 | 90.0% |
| 230 | 2241 | 2241 | 2120 | 1910 | 90.0% |
| 231 | 652 | 652 | 613 | 461 | 70.7% |
| 232 | 230 | 230 | 212 | 165 | 71.7% |
| 233 | 1045 | 1045 | 1033 | 808 | 77.3% |
| 235 | 144 | 144 | 144 | 134 | 93.1% |
| 236 | 353 | 353 | 327 | 318 | 90.1% |
| 238 | 1142 | 1142 | 1125 | 981 | 90.0% |
| 239 | 718 | 718 | 705 | 531 | 74.0% |
| 240 | 424 | 424 | 387 | 315 | 74.3% |
| 241 | 3020 | 3020 | 2660 | 2247 | 74.4% |
| 242 | 177 | 177 | 173 | 154 | 90.0% |
| 244 | 439 | 439 | 437 | 334 | 76.1% |
| 245 | 670 | 670 | 665 | 597 | 90.0% |
| 246 | 1314 | 1314 | 1283 | 1104 | 90.0% |
| 248 | 1805 | 1805 | 1724 | 1540 | 90.0% |
| 252 | 315 | 315 | 313 | 274 | 90.0% |
| 253 | 851 | 851 | 836 | 784 | 92.1% |
| 255 | 98 | 98 | 72 | 59 | 60.2% |
| 256 | 311 | 311 | 281 | 232 | 74.6% |
| 257 | 492 | 492 | 480 | 461 | 93.7% |
| 259 | 111 | 111 | 108 | 91 | 90.0% |
| 263 | 606 | 606 | 590 | 462 | 76.2% |
| 265 | 2673 | 2673 | 2621 | 2271 | 90.0% |
| 266 | 1053 | 1053 | 1027 | 945 | 90.0% |
| 267 | 1078 | 1078 | 1064 | 965 | 90.0% |
| 268 | 321 | 321 | 298 | 222 | 69.2% |
| 269 | 467 | 467 | 456 | 410 | 90.0% |
| 271 | 72 | 72 | 69 | 67 | 93.1% |
| 273 | 1378 | 1378 | 1288 | 1135 | 90.0% |
| 275 | 1061 | 1061 | 1025 | 927 | 90.0% |
| 276 | 269 | 269 | 261 | 247 | 91.8% |
| 277 | 876 | 876 | 833 | 742 | 90.0% |
| 278 | 726 | 726 | 709 | 586 | 90.0% |
| 279 | 1101 | 1101 | 1048 | 974 | 90.0% |
| 280 | 32 | 32 | 30 | 28 | 90.0% |
| 283 | 1124 | 1124 | 1099 | 1009 | 90.0% |
| 284 | 284 | 284 | 283 | 249 | 90.0% |
| 285 | 237 | 237 | 210 | 171 | 72.2% |
| 286 | 403 | 403 | 401 | 340 | 90.0% |
| 288 | 144 | 144 | 134 | 120 | 90.0% |
| 289 | 311 | 311 | 306 | 245 | 78.8% |
| 290 | 77 | 77 | 74 | 66 | 90.0% |
| 291 | 637 | 637 | 611 | 534 | 90.0% |
| 292 | 220 | 220 | 209 | 191 | 90.0% |
| 294 | 1324 | 1324 | 1131 | 982 | 74.2% |
| 295 | 311 | 311 | 305 | 241 | 77.5% |
| 298 | 1414 | 1414 | 1389 | 1322 | 93.5% |
| 299 | 679 | 679 | 640 | 625 | 92.0% |
| 302 | 748 | 748 | 726 | 675 | 90.2% |
| 303 | 297 | 297 | 296 | 259 | 90.0% |
| 304 | 753 | 753 | 729 | 620 | 90.0% |
| 305 | 1050 | 1050 | 1021 | 905 | 90.0% |
| 307 | 918 | 918 | 906 | 791 | 90.0% |
| 308 | 108 | 108 | 107 | 100 | 92.6% |
| 310 | 3009 | 3009 | 2694 | 2462 | 90.0% |
| 311 | 208 | 208 | 145 | 126 | 60.6% |
| 312 | 93 | 93 | 92 | 84 | 90.3% |
| 313 | 151 | 151 | 147 | 122 | 90.0% |
| 314 | 1197 | 1197 | 1179 | 1057 | 90.0% |
| 315 | 1015 | 1015 | 969 | 890 | 90.0% |
| 316 | 241 | 241 | 231 | 214 | 90.0% |
| 317 | 209 | 209 | 202 | 185 | 90.0% |
| 318 | 451 | 451 | 449 | 430 | 95.3% |
| 319 | 130 | 130 | 129 | 117 | 90.0% |
| 320 | 161 | 161 | 160 | 153 | 95.0% |
| 321 | 138 | 138 | 135 | 111 | 80.4% |
| 322 | 163 | 163 | 153 | 131 | 80.4% |
| 323 | 355 | 355 | 341 | 319 | 90.0% |
| 324 | 226 | 226 | 225 | 214 | 94.7% |
| 325 | 1815 | 1815 | 1632 | 1389 | 76.5% |
| 326 | 722 | 722 | 719 | 676 | 93.6% |
| 328 | 556 | 556 | 533 | 440 | 79.1% |
| 329 | 5790 | 5790 | 5645 | 4992 | 90.0% |
| 332 | 443 | 443 | 432 | 394 | 90.0% |
| 333 | 98 | 98 | 97 | 79 | 90.0% |
| 334 | 320 | 320 | 318 | 286 | 90.0% |
| 335 | 527 | 527 | 507 | 461 | 90.0% |
| 336 | 445 | 445 | 438 | 401 | 90.1% |
| 340 | 293 | 293 | 288 | 238 | 90.0% |
| 342 | 380 | 380 | 372 | 329 | 90.0% |
| 343 | 227 | 227 | 207 | 190 | 90.0% |
| 344 | 634 | 634 | 559 | 485 | 76.5% |
| 345 | 120 | 120 | 116 | 96 | 80.0% |
| 347 | 1048 | 1048 | 1031 | 904 | 90.0% |
| 348 | 319 | 319 | 318 | 283 | 90.0% |
| 349 | 318 | 318 | 310 | 255 | 80.2% |
| 351 | 587 | 587 | 577 | 538 | 91.7% |
| 353 | 650 | 650 | 633 | 562 | 90.0% |
| 357 | 1141 | 1141 | 1117 | 941 | 90.0% |
| 358 | 142 | 142 | 142 | 121 | 90.0% |
| 360 | 772 | 772 | 761 | 653 | 90.0% |
| 361 | 598 | 598 | 591 | 499 | 90.0% |
| 362 | 69 | 69 | 67 | 59 | 90.0% |
| 363 | 118 | 118 | 118 | 96 | 90.0% |
| 365 | 42 | 42 | 42 | 40 | 95.2% |
| 366 | 177 | 177 | 170 | 158 | 90.0% |
| 368 | 344 | 344 | 339 | 296 | 90.0% |
| 369 | 234 | 234 | 231 | 214 | 91.5% |
| 370 | 89 | 89 | 85 | 73 | 90.0% |
| 371 | 104 | 104 | 101 | 80 | 76.9% |
| 372 | 1125 | 1125 | 1046 | 933 | 90.0% |
| 375 | 1789 | 1789 | 1736 | 1523 | 90.0% |
| 378 | 65 | 65 | 65 | 59 | 90.8% |
| 379 | 1111 | 1111 | 1085 | 979 | 90.0% |
| 380 | 489 | 489 | 385 | 296 | 60.5% |
| 382 | 675 | 675 | 646 | 604 | 90.0% |
| 384 | 277 | 277 | 258 | 229 | 90.0% |
| 385 | 209 | 209 | 203 | 183 | 90.0% |
| 386 | 178 | 178 | 176 | 162 | 91.0% |
| 388 | 1342 | 1342 | 1335 | 1194 | 90.0% |
| 389 | 206 | 206 | 197 | 176 | 90.0% |
| 390 | 362 | 362 | 353 | 327 | 90.3% |
| 391 | 220 | 220 | 217 | 175 | 79.5% |
| 393 | 758 | 758 | 737 | 693 | 91.4% |
| 394 | 64 | 64 | 64 | 62 | 96.9% |
| 395 | 709 | 709 | 699 | 617 | 90.0% |
| 400 | 235 | 235 | 223 | 194 | 90.0% |
| 404 | 154 | 154 | 153 | 140 | 90.9% |
| 407 | 369 | 369 | 150 | 129 | 35.0% |
| 408 | 617 | 617 | 609 | 533 | 90.0% |
| 409 | 126 | 126 | 122 | 108 | 90.0% |
| 410 | 80 | 80 | 78 | 51 | 63.8% |
| 412 | 463 | 463 | 450 | 366 | 79.0% |
| 414 | 130 | 130 | 128 | 111 | 90.0% |
| 417 | 112 | 112 | 111 | 86 | 76.8% |
| 421 | 644 | 644 | 633 | 593 | 92.1% |
| 422 | 410 | 410 | 406 | 353 | 90.0% |
| 423 | 384 | 384 | 377 | 322 | 90.0% |
| 425 | 235 | 235 | 222 | 175 | 74.5% |
| 427 | 1613 | 1613 | 1588 | 1448 | 90.0% |
| 438 | 551 | 551 | 519 | 422 | 76.6% |
| 441 | 76 | 76 | 76 | 52 | 68.4% |
| 457 | 1186 | 1186 | 1174 | 1098 | 92.6% |
| 463 | 343 | 343 | 301 | 242 | 70.6% |
| 469 | 379 | 379 | 336 | 278 | 73.4% |
| 473 | 1 | 1 | 1 | 0 | 0.0% |
| 480 | 362 | 362 | 351 | 307 | 90.0% |
| 481 | 292 | 292 | 290 | 223 | 76.4% |
| 483 | 879 | 879 | 775 | 609 | 69.3% |
| 489 | 748 | 748 | 679 | 518 | 69.3% |
| 491 | 89 | 89 | 4 | 3 | 3.4% |
| 498 | 550 | 550 | 547 | 506 | 92.0% |
| 504 | 1566 | 1566 | 1535 | 1354 | 90.0% |
| 506 | 312 | 312 | 301 | 278 | 90.0% |
| 509 | 751 | 751 | 739 | 639 | 90.0% |
| 510 | 124 | 124 | 112 | 100 | 90.0% |
| 517 | 317 | 317 | 271 | 229 | 72.2% |
| 534 | 504 | 504 | 502 | 470 | 93.3% |
| 553 | 23 | 23 | 7 | 4 | 17.4% |
| 593 | 122 | 122 | 122 | 110 | 90.2% |
| 598 | 244 | 244 | 244 | 193 | 79.1% |
| 612 | 90 | 90 | 86 | 71 | 78.9% |
| 664 | 321 | 321 | 308 | 236 | 73.5% |
| 704 | 210 | 210 | 202 | 195 | 92.9% |
| 710 | 51 | 51 | 48 | 35 | 68.6% |
| 726 | 297 | 297 | 240 | 146 | 49.2% |
| 738 | 18 | 18 | 14 | 13 | 72.2% |
| 744 | 403 | 403 | 351 | 315 | 78.2% |
| 753 | 302 | 302 | 283 | 241 | 79.8% |
| 757 | 133 | 133 | 123 | 116 | 90.0% |
| 762 | 640 | 640 | 562 | 476 | 74.4% |
| 765 | 251 | 251 | 237 | 204 | 90.0% |
| 775 | 106 | 106 | 103 | 92 | 90.0% |
| 783 | 45 | 45 | 44 | 27 | 60.0% |
| 787 | 153 | 153 | 150 | 136 | 90.0% |
| 791 | 332 | 332 | 330 | 310 | 93.4% |
| 793 | 21 | 21 | 21 | 18 | 90.0% |
| 794 | 66 | 66 | 65 | 45 | 68.2% |
| 798 | 761 | 761 | 716 | 646 | 90.0% |
| 799 | 54 | 54 | 54 | 49 | 90.7% |
| 800 | 188 | 188 | 174 | 155 | 90.0% |
| 801 | 30 | 30 | 30 | 28 | 93.3% |
| 803 | 364 | 364 | 349 | 290 | 79.7% |
| 807 | 234 | 234 | 211 | 196 | 90.0% |
| 818 | 1336 | 1336 | 1307 | 1147 | 90.0% |
| 820 | 94 | 94 | 93 | 79 | 90.0% |
| 821 | 82 | 82 | 81 | 75 | 91.5% |
| 824 | 44 | 44 | 42 | 36 | 90.0% |
| 841 | 93 | 93 | 89 | 77 | 90.0% |
| 852 | 139 | 139 | 139 | 111 | 79.9% |
| 861 | 230 | 230 | 228 | 189 | 90.0% |
| 867 | 930 | 930 | 578 | 476 | 51.2% |
| 871 | 1205 | 1205 | 1193 | 1073 | 90.0% |
| 873 | 278 | 278 | 258 | 222 | 79.9% |
| 894 | 2020 | 2020 | 1911 | 1655 | 90.0% |
| 905 | 853 | 853 | 837 | 632 | 74.1% |
| 907 | 2792 | 2792 | 2633 | 2234 | 80.0% |
| 913 | 1313 | 1313 | 1261 | 1046 | 79.7% |
| 920 | 15 | 15 | 15 | 10 | 66.7% |
| 926 | 37 | 37 | 36 | 30 | 90.0% |
| 927 | 113 | 113 | 109 | 100 | 90.0% |
| 929 | 140 | 140 | 140 | 127 | 90.7% |
| 933 | 204 | 204 | 188 | 162 | 79.4% |
| 945 | 121 | 121 | 119 | 107 | 90.0% |
| 980 | 142 | 142 | 138 | 124 | 90.0% |
| 986 | 141 | 141 | 133 | 120 | 90.0% |
| 992 | 1356 | 1356 | 1330 | 1178 | 90.0% |
| 996 | 905 | 905 | 882 | 805 | 90.0% |
| 1009 | 153 | 153 | 98 | 85 | 55.6% |
| 1017 | 94 | 94 | 94 | 78 | 90.0% |
| 1022 | 242 | 242 | 231 | 208 | 90.0% |
| 1023 | 195 | 195 | 190 | 171 | 90.0% |
| 1026 | 105 | 105 | 90 | 83 | 79.0% |
| 1029 | 159 | 159 | 125 | 100 | 62.9% |
| 1031 | 543 | 543 | 534 | 483 | 90.0% |
| 1036 | 382 | 382 | 378 | 333 | 90.0% |
| 1037 | 104 | 104 | 102 | 91 | 90.0% |
| 1038 | 316 | 316 | 301 | 247 | 78.2% |
| 1049 | 434 | 434 | 384 | 310 | 71.4% |
| 1050 | 833 | 833 | 771 | 648 | 77.8% |
| 1052 | 27 | 27 | 27 | 23 | 90.0% |
| 1055 | 341 | 341 | 331 | 284 | 90.0% |
| 1056 | 758 | 758 | 750 | 665 | 90.0% |
| 1066 | 573 | 573 | 567 | 520 | 90.8% |
| 1067 | 671 | 671 | 647 | 572 | 90.0% |
| 1068 | 1485 | 1485 | 1352 | 1002 | 67.5% |
| 1093 | 69 | 69 | 61 | 51 | 73.9% |
| 1094 | 778 | 778 | 768 | 673 | 90.0% |
| 1100 | 556 | 556 | 540 | 464 | 90.0% |
| 1109 | 1047 | 1047 | 1009 | 933 | 90.0% |
| 1110 | 120 | 120 | 112 | 98 | 90.0% |
| 1112 | 1712 | 1712 | 1661 | 1454 | 90.0% |
| 1120 | 810 | 810 | 808 | 720 | 90.0% |
| 1121 | 1665 | 1665 | 1638 | 1451 | 90.0% |
| 1122 | 411 | 411 | 393 | 339 | 90.0% |
| 1131 | 1024 | 1024 | 992 | 858 | 90.0% |
| 1132 | 186 | 186 | 129 | 117 | 62.9% |
| 1146 | 15 | 15 | 15 | 11 | 73.3% |
| 1155 | 436 | 436 | 433 | 430 | 98.6% |
| 1160 | 1383 | 1383 | 1100 | 914 | 66.1% |
| 1162 | 54 | 54 | 53 | 41 | 75.9% |
| 1163 | 303 | 303 | 291 | 234 | 77.2% |
| 1167 | 2834 | 2834 | 2786 | 2400 | 90.0% |
| 1214 | 147 | 147 | 146 | 142 | 96.6% |
| 1216 | 108 | 108 | 11 | 7 | 6.5% |
| 1229 | 276 | 276 | 269 | 243 | 90.0% |
| 1230 | 146 | 146 | 141 | 132 | 90.4% |
| 1263 | 1 | 1 | 1 | 1 | 100.0% |
| 1276 | 322 | 322 | 304 | 270 | 90.0% |
| 1278 | 103 | 103 | 102 | 86 | 90.0% |
| 1284 | 98 | 98 | 98 | 85 | 90.0% |
| 1287 | 873 | 873 | 851 | 762 | 90.0% |
| 1289 | 38 | 38 | 36 | 31 | 90.0% |
| 1300 | 62 | 62 | 29 | 23 | 37.1% |
| 1302 | 333 | 333 | 7 | 6 | 1.8% |
| 1309 | 72 | 72 | 47 | 44 | 61.1% |
| 1310 | 56 | 56 | 55 | 53 | 94.6% |
| 1314 | 539 | 539 | 232 | 195 | 36.2% |
| 1318 | 73 | 73 | 64 | 58 | 79.5% |
| 1319 | 95 | 95 | 86 | 78 | 90.0% |
| 1333 | 281 | 281 | 281 | 238 | 90.0% |
| 1349 | 57 | 57 | 52 | 35 | 61.4% |
| 1358 | 175 | 175 | 146 | 102 | 58.3% |
| 1359 | 2177 | 2177 | 1701 | 1497 | 68.8% |
| 1364 | 73 | 73 | 72 | 57 | 78.1% |
| 1378 | 141 | 141 | 141 | 119 | 90.0% |
| 1380 | 78 | 78 | 78 | 62 | 79.5% |
| 1382 | 137 | 137 | 96 | 73 | 53.3% |
| 1401 | 604 | 604 | 591 | 504 | 90.0% |
| 1430 | 53 | 53 | 35 | 33 | 62.3% |
| 1444 | 37 | 37 | 34 | 31 | 90.0% |
| 1445 | 1601 | 1601 | 1554 | 1315 | 90.0% |
| 1448 | 21 | 21 | 21 | 18 | 90.0% |
| 1451 | 94 | 94 | 89 | 76 | 90.0% |
| 1456 | 1635 | 1635 | 1568 | 1375 | 90.0% |
| 1461 | 127 | 127 | 123 | 119 | 93.7% |
| 1464 | 275 | 275 | 186 | 144 | 52.4% |
| 1479 | 12 | 12 | 12 | 10 | 90.0% |
| 1490 | 40 | 40 | 16 | 14 | 35.0% |
| 1511 | 647 | 647 | 643 | 553 | 90.0% |
| 1512 | 181 | 181 | 181 | 112 | 61.9% |
| 1514 | 43 | 43 | 43 | 34 | 79.1% |
| 1527 | 20 | 20 | 17 | 13 | 65.0% |
| 1552 | 1709 | 1709 | 1678 | 1551 | 90.8% |
| 1567 | 90 | 90 | 84 | 77 | 90.0% |
| 1570 | 153 | 153 | 137 | 114 | 74.5% |
| 1572 | 51 | 51 | 45 | 36 | 70.6% |
| 1574 | 96 | 96 | 93 | 77 | 80.2% |
| 1582 | 161 | 161 | 158 | 145 | 90.1% |
| 1583 | 4 | 4 | 4 | 3 | 75.0% |
| 1587 | 12 | 12 | 12 | 11 | 91.7% |
| 1594 | 59 | 59 | 57 | 49 | 90.0% |
| 1597 | 27 | 27 | 25 | 22 | 90.0% |
| 1607 | 232 | 232 | 228 | 199 | 90.0% |
| 1610 | 216 | 216 | 213 | 189 | 90.0% |
| 1628 | 32 | 32 | 32 | 31 | 96.9% |
| 1634 | 104 | 104 | 96 | 83 | 79.8% |
| 1635 | 110 | 110 | 103 | 92 | 90.0% |
| 1637 | 309 | 309 | 303 | 247 | 79.9% |
| 1650 | 126 | 126 | 126 | 118 | 93.7% |
| 1654 | 52 | 52 | 41 | 38 | 73.1% |
| 1656 | 132 | 132 | 131 | 119 | 90.2% |
| 1668 | 986 | 986 | 970 | 794 | 90.0% |
| 1672 | 27 | 27 | 27 | 26 | 96.3% |
| 1684 | 1708 | 1708 | 1570 | 1361 | 79.7% |
| 1719 | 1213 | 1213 | 1146 | 973 | 80.2% |
| 1762 | 945 | 945 | 920 | 749 | 79.3% |
| 1784 | 156 | 156 | 153 | 133 | 90.0% |
| 1786 | 66 | 66 | 66 | 58 | 90.0% |
| 1792 | 840 | 840 | 809 | 656 | 78.1% |
| 1806 | 9 | 9 | 6 | 5 | 55.6% |
| 1809 | 739 | 739 | 731 | 627 | 90.0% |
| 1812 | 731 | 731 | 691 | 592 | 90.0% |
| 1831 | 75 | 75 | 73 | 70 | 93.3% |
| 1834 | 42 | 42 | 41 | 30 | 71.4% |
| 1847 | 98 | 98 | 90 | 78 | 79.6% |
| 1849 | 144 | 144 | 135 | 115 | 79.9% |
| 1879 | 191 | 191 | 163 | 153 | 80.1% |
| 1900 | 1 | 1 | 1 | 0 | 0.0% |
| 1904 | 28 | 28 | 28 | 22 | 78.6% |
| 1912 | 635 | 635 | 623 | 559 | 90.0% |
| 1930 | 110 | 110 | 100 | 90 | 90.0% |
| 1955 | 116 | 116 | 115 | 100 | 90.0% |
| 1967 | 33 | 33 | 24 | 23 | 69.7% |
| 1968 | 32 | 32 | 30 | 29 | 90.6% |
| 1970 | 8 | 8 | 8 | 8 | 100.0% |
| 1972 | 2 | 2 | 0 | 0 | 0.0% |
| 1977 | 27 | 27 | 27 | 25 | 92.6% |
| 1980 | 49 | 49 | 48 | 39 | 79.6% |
| 1989 | 108 | 108 | 105 | 92 | 90.0% |
| 2003 | 4 | 4 | 2 | 2 | 50.0% |
| 2008 | 6 | 6 | 6 | 6 | 100.0% |
| 2010 | 10 | 10 | 10 | 10 | 100.0% |
| 2011 | 21 | 21 | 20 | 17 | 90.0% |
| 2017 | 33 | 33 | 32 | 29 | 90.0% |
| 2020 | 10 | 10 | 9 | 9 | 90.0% |
| 2025 | 268 | 268 | 264 | 231 | 90.0% |
| 2028 | 194 | 194 | 187 | 165 | 90.0% |
| 2029 | 88 | 88 | 81 | 77 | 90.0% |
| 2034 | 53 | 53 | 51 | 49 | 92.5% |
| 2041 | 8 | 8 | 7 | 6 | 75.0% |
| 2049 | 41 | 41 | 39 | 31 | 75.6% |
| 2058 | 291 | 291 | 280 | 256 | 90.0% |
| 2072 | 33 | 33 | 29 | 29 | 90.0% |
| 2073 | 740 | 740 | 674 | 674 | 91.1% |
| 2076 | 23 | 23 | 23 | 23 | 100.0% |
| 2078 | 32 | 32 | 31 | 27 | 90.0% |
| 2080 | 3 | 3 | 3 | 3 | 100.0% |
| 2081 | 2 | 2 | 2 | 2 | 100.0% |
| 2116 | 109 | 109 | 99 | 88 | 90.0% |
| 2117 | 23 | 23 | 22 | 16 | 69.6% |
| 2118 | 93 | 93 | 84 | 77 | 90.0% |
| 2126 | 135 | 135 | 130 | 118 | 90.0% |
| 2127 | 90 | 90 | 87 | 76 | 90.0% |
| 2129 | 140 | 140 | 137 | 115 | 90.0% |
| 2133 | 356 | 356 | 353 | 307 | 90.0% |
| 2134 | 31 | 31 | 25 | 23 | 74.2% |
| 2137 | 26 | 26 | 26 | 23 | 90.0% |
| 2139 | 163 | 163 | 11 | 10 | 6.1% |
| 2141 | 348 | 348 | 332 | 282 | 90.0% |
| 2143 | 996 | 996 | 993 | 888 | 90.0% |
| 2148 | 124 | 124 | 123 | 110 | 90.0% |
| 2150 | 1341 | 1341 | 1313 | 1172 | 90.0% |
| 2153 | 158 | 158 | 148 | 133 | 90.0% |
| 2163 | 205 | 205 | 192 | 180 | 90.0% |
| 2170 | 318 | 318 | 318 | 250 | 78.6% |
| 2174 | 5229 | 5229 | 4801 | 4150 | 79.4% |
| 2175 | 191 | 191 | 189 | 168 | 90.0% |
| 2178 | 407 | 407 | 403 | 318 | 78.1% |
| 2180 | 974 | 974 | 961 | 825 | 90.0% |
| 2183 | 175 | 175 | 175 | 163 | 93.1% |
| 2187 | 24 | 24 | 24 | 23 | 95.8% |
| 2188 | 19 | 19 | 19 | 18 | 94.7% |
| 2189 | 21 | 21 | 21 | 19 | 90.5% |
| 2191 | 62 | 62 | 62 | 57 | 91.9% |
| 2198 | 49 | 49 | 45 | 43 | 90.0% |
| 2200 | 33 | 33 | 31 | 28 | 90.0% |
| 2203 | 109 | 109 | 100 | 90 | 90.0% |
| 2205 | 53 | 53 | 49 | 47 | 90.0% |
| 2207 | 2326 | 2326 | 1995 | 1835 | 78.9% |
| 2224 | 714 | 714 | 701 | 623 | 90.0% |
| 2228 | 19 | 19 | 8 | 7 | 36.8% |
| 2230 | 113 | 113 | 113 | 102 | 90.3% |
| 2232 | 5 | 5 | 3 | 3 | 60.0% |
| 2246 | 233 | 233 | 227 | 173 | 74.2% |
| 2252 | 64 | 64 | 17 | 12 | 18.8% |
| 2263 | 25 | 25 | 23 | 23 | 92.0% |
| 2264 | 2 | 2 | 1 | 1 | 50.0% |
| 2296 | 301 | 301 | 296 | 266 | 90.0% |
| 2299 | 548 | 548 | 535 | 436 | 79.6% |
| 2320 | 967 | 967 | 950 | 863 | 90.0% |
| 2366 | 70 | 70 | 67 | 63 | 90.0% |
| 2368 | 68 | 68 | 68 | 66 | 97.1% |
| 2374 | 2 | 2 | 2 | 2 | 100.0% |
| 2378 | 19 | 19 | 19 | 17 | 90.0% |
| 2379 | 23 | 23 | 22 | 21 | 91.3% |
| 2381 | 155 | 155 | 151 | 147 | 94.8% |
| 2388 | 6 | 6 | 5 | 4 | 66.7% |
| 2389 | 1 | 1 | 0 | 0 | 0.0% |
| 2415 | 129 | 129 | 127 | 124 | 96.1% |
| 2420 | 124 | 124 | 124 | 109 | 90.0% |
| 2436 | 181 | 181 | 180 | 167 | 92.3% |
| 2438 | 59 | 59 | 59 | 55 | 93.2% |
| 2444 | 2 | 2 | 1 | 1 | 50.0% |
| 2457 | 224 | 224 | 224 | 211 | 94.2% |
| 2474 | 263 | 263 | 234 | 179 | 68.1% |
| 2495 | 67 | 67 | 67 | 62 | 92.5% |
| 2514 | 13850 | 13850 | 6711 | 5493 | 39.7% |
| 2525 | 765 | 765 | 761 | 696 | 91.0% |
| 2572 | 634 | 634 | 559 | 485 | 76.5% |
| 2654 | 38 | 38 | 36 | 36 | 94.7% |
| 2694 | 1 | 1 | 1 | 1 | 100.0% |
| 2699 | 19 | 19 | 19 | 18 | 94.7% |
| 2700 | 441 | 441 | 438 | 387 | 90.0% |
| 2702 | 428 | 428 | 425 | 372 | 90.0% |
| 2703 | 493 | 493 | 483 | 443 | 90.0% |
| 2704 | 340 | 340 | 338 | 296 | 90.0% |
| 2707 | 1 | 1 | 1 | 1 | 100.0% |
| 2709 | 1052 | 1052 | 1040 | 900 | 90.0% |
| 2714 | 254 | 254 | 247 | 194 | 76.4% |
| 2717 | 125 | 125 | 124 | 107 | 90.0% |
| 2718 | 1952 | 1952 | 1934 | 1720 | 90.0% |
| 2720 | 126 | 126 | 108 | 97 | 77.0% |
| 2721 | 1119 | 1119 | 1087 | 787 | 70.3% |
| 2723 | 347 | 347 | 338 | 290 | 90.0% |
| 2728 | 264 | 264 | 264 | 248 | 93.9% |
| 2732 | 434 | 434 | 428 | 383 | 90.0% |
| 2737 | 43 | 43 | 42 | 31 | 72.1% |
| 2745 | 120 | 120 | 120 | 112 | 93.3% |
| 2746 | 126 | 126 | 119 | 105 | 90.0% |
| 2757 | 225 | 225 | 223 | 193 | 90.0% |
| 2764 | 187 | 187 | 171 | 133 | 71.1% |
| 2766 | 156 | 156 | 148 | 119 | 76.3% |
| 2767 | 42 | 42 | 41 | 31 | 73.8% |
| 2768 | 1680 | 1680 | 1668 | 1391 | 90.0% |
| 2769 | 63 | 63 | 60 | 38 | 60.3% |
| 2771 | 339 | 339 | 336 | 263 | 77.6% |
| 2775 | 766 | 766 | 756 | 674 | 90.0% |
| 2779 | 226 | 226 | 219 | 194 | 90.0% |
| 2782 | 189 | 189 | 181 | 136 | 72.0% |
| 2788 | 207 | 207 | 202 | 162 | 78.3% |
| 2790 | 488 | 488 | 475 | 347 | 71.1% |
| 2794 | 52 | 52 | 50 | 47 | 90.4% |
| 2795 | 134 | 134 | 134 | 108 | 90.0% |
| 2849 | 383 | 383 | 375 | 341 | 90.0% |
| 2855 | 131 | 131 | 128 | 108 | 90.0% |
| 2856 | 55 | 55 | 50 | 42 | 76.4% |
| 2857 | 22 | 22 | 22 | 22 | 100.0% |
| 2865 | 556 | 556 | 527 | 486 | 90.0% |
| 2872 | 41 | 41 | 40 | 40 | 97.6% |
| 2873 | 7 | 7 | 4 | 4 | 57.1% |
| 2892 | 273 | 273 | 227 | 205 | 75.1% |
| 2893 | 266 | 266 | 264 | 236 | 90.0% |
| 2928 | 491 | 491 | 485 | 457 | 93.1% |
| 2929 | 85 | 85 | 84 | 73 | 90.0% |
| 2933 | 177 | 177 | 175 | 160 | 90.4% |
| 2945 | 210 | 210 | 182 | 140 | 66.7% |
| 2947 | 808 | 808 | 778 | 670 | 90.0% |
| 2948 | 471 | 471 | 445 | 385 | 90.0% |
| 2949 | 162 | 162 | 125 | 110 | 67.9% |
| 2951 | 205 | 205 | 200 | 170 | 90.0% |
| 2958 | 36 | 36 | 36 | 33 | 91.7% |
| 2959 | 52 | 52 | 51 | 30 | 57.7% |
| 2966 | 120 | 120 | 112 | 91 | 75.8% |
| 2969 | 70 | 70 | 69 | 51 | 72.9% |
| 2970 | 100 | 100 | 100 | 94 | 94.0% |
| 2988 | 93 | 93 | 62 | 53 | 57.0% |
| 2989 | 9 | 9 | 9 | 7 | 77.8% |
| 2997 | 896 | 896 | 868 | 734 | 90.0% |
| 3010 | 347 | 347 | 331 | 268 | 77.2% |
| 3012 | 183 | 183 | 178 | 152 | 90.0% |
| 3020 | 4 | 4 | 4 | 4 | 100.0% |
| 3048 | 19 | 19 | 18 | 14 | 73.7% |
| 3052 | 135 | 135 | 131 | 102 | 75.6% |
| 3077 | 79 | 79 | 76 | 56 | 70.9% |
| 3079 | 134 | 134 | 133 | 123 | 91.8% |
| 3111 | 71 | 71 | 71 | 64 | 90.1% |
| 3131 | 212 | 212 | 209 | 169 | 79.7% |
| 3133 | 89 | 89 | 89 | 66 | 74.2% |
| 3164 | 50 | 50 | 47 | 44 | 90.0% |
| 3177 | 165 | 165 | 162 | 148 | 90.0% |
| 3187 | 73 | 73 | 69 | 51 | 69.9% |
| 3210 | 315 | 315 | 274 | 237 | 75.2% |
| 3255 | 75 | 75 | 60 | 41 | 54.7% |
| 3261 | 151 | 151 | 151 | 130 | 90.0% |
| 3262 | 44 | 44 | 40 | 31 | 70.5% |
| 3264 | 29 | 29 | 29 | 22 | 75.9% |
| 3265 | 177 | 177 | 170 | 138 | 78.0% |
| 3310 | 197 | 197 | 182 | 143 | 72.6% |
| 3359 | 125 | 125 | 121 | 82 | 65.6% |
| 3389 | 33 | 33 | 22 | 22 | 66.7% |
| 3397 | 235 | 235 | 215 | 92 | 39.1% |
| 3401 | 112 | 112 | 46 | 40 | 35.7% |
| 3428 | 459 | 459 | 456 | 424 | 92.4% |
| 3433 | 205 | 205 | 192 | 162 | 79.0% |
| 3440 | 266 | 266 | 263 | 234 | 90.0% |
| 3444 | 213 | 213 | 204 | 182 | 90.0% |
| 3445 | 56 | 56 | 51 | 48 | 90.0% |
| 3449 | 44 | 44 | 44 | 31 | 70.5% |
| 3456 | 348 | 348 | 253 | 213 | 61.2% |
| 3469 | 263 | 263 | 257 | 229 | 90.0% |
| 3482 | 108 | 108 | 107 | 97 | 90.0% |
| 3484 | 334 | 334 | 308 | 295 | 90.0% |
| 3498 | 20 | 20 | 18 | 17 | 90.0% |
| 3507 | 55 | 55 | 54 | 50 | 90.9% |
| 3519 | 355 | 355 | 349 | 257 | 72.4% |
| 3521 | 80 | 80 | 79 | 72 | 90.0% |
| 3523 | 124 | 124 | 122 | 103 | 90.0% |
| 3527 | 256 | 256 | 255 | 220 | 90.0% |
| 3530 | 197 | 197 | 142 | 117 | 59.4% |
| 3533 | 9 | 9 | 4 | 1 | 11.1% |
| 3538 | 110 | 110 | 108 | 96 | 90.0% |
| 3551 | 313 | 313 | 294 | 248 | 79.2% |
| 3552 | 23 | 23 | 2 | 2 | 8.7% |
| 3553 | 53 | 53 | 36 | 27 | 50.9% |
| 3554 | 27 | 27 | 19 | 14 | 51.9% |
| 3573 | 146 | 146 | 145 | 118 | 90.0% |
| 3579 | 143 | 143 | 142 | 107 | 74.8% |
| 3583 | 1125 | 1125 | 1111 | 940 | 90.0% |
| 3587 | 80 | 80 | 78 | 73 | 91.3% |
| 3591 | 38 | 38 | 36 | 32 | 90.0% |
| 3593 | 241 | 241 | 238 | 206 | 90.0% |
| 3594 | 127 | 127 | 124 | 107 | 90.0% |
| 3595 | 792 | 792 | 786 | 710 | 90.0% |
| 3596 | 110 | 110 | 110 | 102 | 92.7% |
| 3597 | 257 | 257 | 247 | 230 | 90.0% |
| 3598 | 71 | 71 | 69 | 67 | 94.4% |
| 3600 | 40 | 40 | 40 | 28 | 70.0% |
| 3601 | 747 | 747 | 734 | 680 | 91.0% |
| 3602 | 91 | 91 | 85 | 79 | 90.0% |
| 3603 | 125 | 125 | 125 | 109 | 90.0% |
| 3604 | 12 | 12 | 12 | 11 | 91.7% |
| 3605 | 146 | 146 | 144 | 129 | 90.0% |
| 3606 | 194 | 194 | 193 | 140 | 72.2% |
| 3607 | 559 | 559 | 553 | 504 | 90.2% |
| 3608 | 236 | 236 | 180 | 160 | 67.8% |
| 3609 | 50 | 50 | 49 | 42 | 90.0% |
| 3625 | 68 | 68 | 68 | 50 | 73.5% |
| 3626 | 58 | 58 | 55 | 53 | 91.4% |
| 3633 | 82 | 82 | 82 | 62 | 75.6% |
| 3639 | 948 | 948 | 931 | 792 | 90.0% |
| 3658 | 10 | 10 | 8 | 8 | 80.0% |
| 3659 | 93 | 93 | 85 | 79 | 90.0% |
| 3687 | 145 | 145 | 145 | 94 | 64.8% |
| 3702 | 796 | 796 | 770 | 677 | 90.0% |
| 3728 | 3 | 3 | 3 | 3 | 100.0% |
| 3769 | 748 | 748 | 721 | 663 | 90.0% |
| 3794 | 290 | 290 | 278 | 225 | 77.6% |
| 3826 | 157 | 157 | 94 | 66 | 42.0% |
| 3847 | 909 | 909 | 886 | 707 | 77.8% |
| 3862 | 11 | 11 | 11 | 7 | 63.6% |
| 3879 | 236 | 236 | 210 | 183 | 77.5% |
| 3904 | 966 | 966 | 953 | 868 | 90.0% |
| 3932 | 87 | 87 | 69 | 60 | 69.0% |
| 3942 | 131 | 131 | 129 | 123 | 93.9% |
| 3959 | 71 | 71 | 71 | 56 | 78.9% |
| 3969 | 56 | 56 | 56 | 56 | 100.0% |
| 3972 | 183 | 183 | 183 | 169 | 92.3% |
| 3973 | 254 | 254 | 250 | 209 | 90.0% |
| 3975 | 35 | 35 | 34 | 33 | 94.3% |
| 3976 | 384 | 384 | 373 | 333 | 90.0% |
| 3977 | 892 | 892 | 832 | 637 | 71.4% |
| 3978 | 515 | 515 | 474 | 403 | 78.3% |
| 3979 | 530 | 530 | 514 | 425 | 80.2% |
| 3980 | 267 | 267 | 256 | 221 | 90.0% |
| 3981 | 1933 | 1933 | 1894 | 1634 | 90.0% |
| 3982 | 428 | 428 | 422 | 389 | 90.9% |
| 3983 | 293 | 293 | 278 | 259 | 90.0% |
| 3984 | 54 | 54 | 52 | 38 | 70.4% |
| 3985 | 47 | 47 | 47 | 45 | 95.7% |
| 3998 | 104 | 104 | 99 | 83 | 79.8% |
| 4014 | 134 | 134 | 131 | 128 | 95.5% |
| 4018 | 107 | 107 | 102 | 88 | 90.0% |
| 4035 | 138 | 138 | 138 | 125 | 90.6% |
| 4039 | 106 | 106 | 105 | 80 | 75.5% |
| 4068 | 20 | 20 | 14 | 13 | 65.0% |
| 4088 | 222 | 222 | 214 | 185 | 90.0% |
| 4122 | 81 | 81 | 81 | 69 | 90.0% |
| 4126 | 70 | 70 | 69 | 63 | 90.0% |
| 4220 | 131 | 131 | 129 | 123 | 93.9% |
| 4221 | 77 | 77 | 71 | 55 | 71.4% |
| 4235 | 100 | 100 | 73 | 61 | 61.0% |
| 7685 | 151 | 151 | 149 | 135 | 90.0% |
| 7718 | 80 | 80 | 66 | 52 | 65.0% |
| 7722 | 76 | 76 | 73 | 57 | 75.0% |
| 7728 | 53 | 53 | 48 | 37 | 69.8% |
| 7734 | 255 | 255 | 252 | 238 | 93.3% |
| 7738 | 865 | 865 | 842 | 762 | 90.0% |
| 7758 | 28 | 28 | 27 | 25 | 90.0% |
| 7765 | 399 | 399 | 385 | 320 | 80.2% |
| 7766 | 512 | 512 | 504 | 450 | 90.0% |
| 7772 | 435 | 435 | 423 | 341 | 78.4% |
| 7780 | 6 | 6 | 5 | 3 | 50.0% |
| 7782 | 18 | 18 | 18 | 18 | 100.0% |
| 7785 | 283 | 283 | 279 | 239 | 90.0% |
| 7802 | 545 | 545 | 533 | 454 | 90.0% |
| 7807 | 149 | 149 | 149 | 97 | 65.1% |
| 7821 | 71 | 71 | 68 | 53 | 74.6% |
| 7833 | 135 | 135 | 132 | 96 | 71.1% |
| 7834 | 150 | 150 | 150 | 122 | 90.0% |
| 7845 | 219 | 219 | 205 | 166 | 75.8% |
| 7857 | 7 | 7 | 0 | 0 | 0.0% |
| 7878 | 46 | 46 | 32 | 28 | 60.9% |
| 7885 | 438 | 438 | 432 | 377 | 90.0% |
| 7886 | 113 | 113 | 110 | 92 | 90.0% |
| 7888 | 402 | 402 | 400 | 362 | 90.0% |
| 7892 | 151 | 151 | 127 | 117 | 77.5% |
| 7910 | 1 | 1 | 1 | 1 | 100.0% |
| 7911 | 28 | 28 | 26 | 24 | 90.0% |
| 7913 | 71 | 71 | 67 | 56 | 78.9% |
| 7919 | 29 | 29 | 26 | 23 | 79.3% |
| 7920 | 73 | 73 | 67 | 59 | 90.0% |
| 7929 | 537 | 537 | 534 | 497 | 92.6% |
| 7931 | 410 | 410 | 401 | 365 | 90.0% |
| 7942 | 734 | 734 | 724 | 717 | 97.7% |
| 7955 | 131 | 131 | 131 | 115 | 90.0% |
| 7964 | 43 | 43 | 31 | 24 | 55.8% |
| 7985 | 62 | 62 | 50 | 47 | 75.8% |
| 7997 | 234 | 234 | 231 | 206 | 90.0% |
| 7998 | 34 | 34 | 32 | 26 | 76.5% |
| 8000 | 833 | 833 | 806 | 705 | 90.0% |
| 8005 | 275 | 275 | 274 | 243 | 90.0% |
| 8018 | 210 | 210 | 208 | 208 | 99.0% |
| 8027 | 64 | 64 | 60 | 49 | 76.6% |
| 8029 | 337 | 337 | 310 | 275 | 90.0% |
| 8030 | 45 | 45 | 44 | 32 | 71.1% |
| 8063 | 49 | 49 | 45 | 39 | 79.6% |
| 8067 | 335 | 335 | 333 | 277 | 90.0% |
| 8079 | 216 | 216 | 200 | 171 | 79.2% |
| 8102 | 71 | 71 | 67 | 65 | 91.5% |
| 8111 | 125 | 125 | 111 | 86 | 68.8% |
| 8119 | 350 | 350 | 124 | 107 | 30.6% |
| 8129 | 228 | 228 | 227 | 163 | 71.5% |
| 8130 | 170 | 170 | 167 | 142 | 90.0% |
| 8131 | 716 | 716 | 698 | 634 | 90.0% |
| 8132 | 646 | 646 | 633 | 570 | 90.0% |
| 8133 | 837 | 837 | 827 | 731 | 90.0% |
| 8134 | 501 | 501 | 500 | 442 | 90.0% |
| 8135 | 447 | 447 | 443 | 412 | 92.2% |
| 8136 | 236 | 236 | 235 | 206 | 90.0% |
| 8142 | 86 | 86 | 79 | 68 | 79.1% |
| 8143 | 108 | 108 | 108 | 99 | 91.7% |
| 8149 | 1 | 1 | 0 | 0 | 0.0% |
| 8160 | 674 | 674 | 639 | 570 | 90.0% |
| 8163 | 56 | 56 | 55 | 45 | 80.4% |
| 8166 | 99 | 99 | 74 | 61 | 61.6% |
| 8167 | 30 | 30 | 14 | 8 | 26.7% |
| 8180 | 91 | 91 | 91 | 79 | 90.0% |
| 8181 | 91 | 91 | 91 | 81 | 90.0% |
| 8199 | 1410 | 1410 | 1383 | 1151 | 90.0% |
| 8228 | 352 | 352 | 350 | 319 | 90.6% |
| 8229 | 83 | 83 | 82 | 79 | 95.2% |
| 8242 | 4937 | 4937 | 4715 | 4097 | 90.0% |
| 8260 | 60 | 60 | 58 | 40 | 66.7% |
| 8261 | 215 | 215 | 211 | 190 | 90.0% |
| 8262 | 69 | 69 | 67 | 55 | 79.7% |
| 8263 | 515 | 515 | 487 | 461 | 90.0% |
| 8265 | 888 | 888 | 881 | 811 | 91.3% |
| 8277 | 208 | 208 | 207 | 186 | 90.0% |
| 8282 | 20 | 20 | 16 | 11 | 55.0% |
| 8284 | 25 | 25 | 23 | 21 | 90.0% |
| 8288 | 8 | 8 | 8 | 8 | 100.0% |
| 8294 | 115 | 115 | 111 | 87 | 75.7% |
| 8295 | 83 | 83 | 82 | 74 | 90.0% |
| 8300 | 2 | 2 | 1 | 1 | 50.0% |
| 8301 | 6 | 6 | 3 | 2 | 33.3% |
| 8302 | 7 | 7 | 7 | 5 | 71.4% |
| 8305 | 14 | 14 | 14 | 14 | 100.0% |
| 8308 | 5 | 5 | 5 | 5 | 100.0% |
| 8313 | 347 | 347 | 341 | 315 | 90.8% |
| 8320 | 21 | 21 | 21 | 19 | 90.5% |
| 8323 | 191 | 191 | 144 | 110 | 57.6% |
| 8330 | 1 | 1 | 1 | 1 | 100.0% |
| 8332 | 8 | 8 | 8 | 7 | 90.0% |
| 8334 | 2 | 2 | 2 | 1 | 50.0% |
| 8355 | 220 | 220 | 218 | 188 | 90.0% |
| 8369 | 242 | 242 | 221 | 209 | 90.0% |
| 8373 | 210 | 210 | 209 | 168 | 80.0% |
| 8387 | 317 | 317 | 289 | 260 | 90.0% |
| 8396 | 744 | 744 | 724 | 602 | 90.0% |
| 8397 | 345 | 345 | 331 | 276 | 80.0% |
| 8399 | 44 | 44 | 43 | 42 | 95.5% |
| 8401 | 114 | 114 | 108 | 97 | 90.0% |
| 8403 | 429 | 429 | 407 | 346 | 90.0% |
| 8405 | 70 | 70 | 68 | 61 | 90.0% |
| 8407 | 143 | 143 | 141 | 99 | 69.2% |
| 8411 | 882 | 882 | 867 | 780 | 90.0% |
| 8412 | 7 | 7 | 7 | 7 | 100.0% |
| 8414 | 36 | 36 | 35 | 33 | 91.7% |
| 8415 | 12 | 12 | 12 | 12 | 100.0% |
| 8419 | 255 | 255 | 245 | 218 | 90.0% |
| 8421 | 161 | 161 | 156 | 127 | 78.9% |
| 8425 | 43 | 43 | 43 | 35 | 90.0% |
| 8426 | 156 | 156 | 151 | 121 | 77.6% |
| 8427 | 49 | 49 | 29 | 28 | 57.1% |
| 8430 | 18 | 18 | 16 | 13 | 72.2% |
| 8432 | 15 | 15 | 15 | 15 | 100.0% |
| 8438 | 24 | 24 | 14 | 4 | 16.7% |
| 8441 | 28 | 28 | 24 | 15 | 53.6% |
| 8504 | 11 | 11 | 10 | 6 | 54.5% |
| 8506 | 2865 | 2865 | 2797 | 2474 | 90.0% |
| 8507 | 331 | 331 | 320 | 284 | 90.0% |
| 8508 | 150 | 150 | 146 | 137 | 91.3% |
| 8510 | 1419 | 1419 | 1398 | 1254 | 90.0% |
| 8511 | 737 | 737 | 724 | 584 | 79.2% |
| 8512 | 603 | 603 | 578 | 505 | 90.0% |
| 8513 | 83 | 83 | 76 | 60 | 72.3% |
| 8537 | 109 | 109 | 108 | 67 | 61.5% |
| 8538 | 348 | 348 | 342 | 283 | 90.0% |
| 8542 | 638 | 638 | 609 | 515 | 90.0% |
| 8546 | 113 | 113 | 113 | 101 | 90.0% |
| 8550 | 190 | 190 | 189 | 155 | 90.0% |
| 8551 | 195 | 195 | 194 | 180 | 92.3% |
| 8553 | 30 | 30 | 30 | 29 | 96.7% |
| 8559 | 71 | 71 | 70 | 66 | 93.0% |
| 8561 | 371 | 371 | 363 | 321 | 90.0% |
| 8563 | 71 | 71 | 70 | 64 | 90.1% |
| 8566 | 19 | 19 | 19 | 15 | 78.9% |
| 8568 | 39 | 39 | 38 | 31 | 79.5% |
| 8570 | 9 | 9 | 9 | 8 | 90.0% |
| 8571 | 136 | 136 | 126 | 112 | 90.0% |
| 8573 | 62 | 62 | 51 | 43 | 69.4% |
| 8575 | 94 | 94 | 88 | 87 | 92.6% |
| 8577 | 33 | 33 | 33 | 21 | 63.6% |
| 8579 | 6 | 6 | 6 | 4 | 66.7% |
| 8580 | 244 | 244 | 215 | 179 | 73.4% |
| 8598 | 1666 | 1666 | 1623 | 1238 | 74.3% |
| 8608 | 46 | 46 | 28 | 20 | 43.5% |
| 8611 | 68 | 68 | 64 | 46 | 67.6% |
| 8618 | 166 | 166 | 166 | 146 | 90.0% |
| 8624 | 689 | 689 | 670 | 577 | 90.0% |
| 8626 | 13 | 13 | 13 | 11 | 90.0% |
| 8632 | 297 | 297 | 286 | 173 | 58.2% |
| 8635 | 17 | 17 | 13 | 12 | 70.6% |
| 8636 | 5 | 5 | 5 | 5 | 100.0% |
| 8638 | 4 | 4 | 4 | 4 | 100.0% |
| 8639 | 33 | 33 | 32 | 31 | 93.9% |
| 8640 | 9 | 9 | 9 | 9 | 100.0% |
| 8641 | 10 | 10 | 10 | 10 | 100.0% |
| 8644 | 6 | 6 | 6 | 6 | 100.0% |
| 8645 | 4 | 4 | 3 | 3 | 75.0% |
| 8650 | 152 | 152 | 151 | 140 | 92.1% |
| 8651 | 191 | 191 | 187 | 151 | 79.1% |
| 8653 | 2 | 2 | 2 | 1 | 50.0% |

Summary statistics for proportion of patients with viral suppression across providers

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Year | N | Mean | SD | Min. | 10th percentile | Lower quartile | Median | Upper quartile | 90th percentile | Max. |
| 2010 | 846 | 60.6% | 23.8% | 0.0% | 19.5% | 51.9% | 67.8% | 77.1% | 82.8% | 100.0% |
| 2011 | 811 | 64.7% | 22.1% | 0.0% | 31.9% | 54.9% | 71.4% | 80.0% | 84.9% | 100.0% |
| 2012 | 816 | 69.9% | 20.3% | 0.0% | 40.2% | 64.3% | 75.6% | 82.1% | 88.0% | 100.0% |
| 2013 | 823 | 76.1% | 17.0% | 0.0% | 57.1% | 71.2% | 80.7% | 85.9% | 90.2% | 100.0% |
| 2014 | 813 | 80.3% | 15.5% | 0.0% | 65.0% | 76.5% | 84.2% | 89.1% | 93.1% | 100.0% |

*Data source*

The data source for this analysis is the Ryan White HIV/AIDS Program Services Report (RSR). The Ryan White HIV/AIDS Program supports a comprehensive system of care that ensures ongoing access to high quality HIV care, treatment, and support services. The RSR dataset is the HRSA HIV/AIDS Bureau’s primary source of annual, provider- and client-level data collected from more than 2,000 funded grant recipients and subrecipients. Since 2010, RSR data have been used to assess the numbers and types of clients receiving services and their HIV-related outcomes. The analysis includes data reported to the RSR for clients living with HIV served by the Ryan White HIV/AIDS Program during calendar years 2010 through 2014. The data are inclusive of all Ryan White HIV/AIDS Program providers delivering outpatient ambulatory medical care to clients living with HIV.

Summary of measured entities (providers) and patients, by year

|  |  |  |
| --- | --- | --- |
| Year | Providers (N) | Patients (N) |
| 2010 | 846 | 324,455 |
| 2011 | 811 | 327,744 |
| 2012 | 816 | 335,408 |
| 2013 | 823 | 327,618 |
| 2014 | 813 | 316,087 |

1b.3. If no or limited performance data on the measure as specified is reported in 1b2, then provide a summary of data from the literature that indicates opportunity for improvement or overall less than optimal performance on the specific focus of measurement. Include citations. N/A

1b.4. Provide disparities data from the measure as specified (current and over time) by population group, e.g., by race/ethnicity, gender, age, insurance status, socioeconomic status, and/or disability. (This is required for maintenance of endorsement.

*Performance scores*

Client-level performance scores for viral load suppression for 2010-2014 (overall and by population group) are presented below.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Viral suppression by select characteristics and key NHAS populations** | | | | | | | | | | | | | | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Viral suppression overall* | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2010 | | | 2011 | | | 2012 | | | 2013 | | | 2014 | | |
|  | N | n | % | N | n | % | N | n | % | N | n | % | N | n | % |
| Total number of patients | 324,455 | ─ | ─ | 327,744 | ─ | ─ | 335,408 | ─ | ─ | 327,618 | ─ | ─ | 316,087 | ─ | ─ |
| Patients with 1 or more medical visits during measurement year (n) | 324,455 | 324,455 | 100.0 | 327,744 | 327,744 | 100.0 | 335,408 | 335,408 | 100.0 | 327,618 | 327,618 | 100.0 | 316,087 | 316,087 | 100.0 |
| Patient had viral load test during measurement year | 324,455 | 264,630 | 81.6 | 327,744 | 273,241 | 83.4 | 335,408 | 289,563 | 86.3 | 327,618 | 297,066 | 90.7 | 316,087 | 293,237 | 92.8 |
| Patients with viral suppression (a) | 264,630 | 200,584 | 61.8 | 273,241 | 214,650 | 65.5 | 289,563 | 234,505 | 69.9 | 297,066 | 249,436 | 76.1 | 293,237 | 255,342 | 80.8 |
| *Viral suppression by subgroup* | | | | | | | | | | | | | | | |
|  | 2010 | | | 2011 | | | 2012 | | | 2013 | | | 2014 | | |
|  | N | n | % | N | n | % | N | n | % | N | n | % | N | n | % |
| **AGE GROUP** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <13 | 3,696 | 1,340 | 36.3 | 3,634 | 1,108 | 30.5 | 3,138 | 1,138 | 36.3 | 2,663 | 1,008 | 37.9 | 2,649 | 940 | 35.5 |
| 13–14 | 619 | 377 | 60.9 | 598 | 414 | 69.2 | 466 | 355 | 76.2 | 359 | 293 | 81.6 | 334 | 280 | 83.8 |
| 15–19 | 3,629 | 1,851 | 51.0 | 3,469 | 1,867 | 53.8 | 3,000 | 1,720 | 57.3 | 2,548 | 1,666 | 65.4 | 2,123 | 1,519 | 71.5 |
| 20–24 | 13,581 | 5,683 | 41.8 | 14,316 | 6,711 | 46.9 | 15,254 | 7,731 | 50.7 | 15,095 | 9,091 | 60.2 | 12,272 | 8,375 | 68.2 |
| 25–29 | 21,278 | 10,403 | 48.9 | 22,437 | 12,005 | 53.5 | 24,155 | 14,080 | 58.3 | 24,848 | 16,467 | 66.3 | 23,475 | 17,013 | 72.5 |
| 30–34 | 27,698 | 15,295 | 55.2 | 28,423 | 16,904 | 59.5 | 29,158 | 18,527 | 63.5 | 28,648 | 20,187 | 70.5 | 26,668 | 20,250 | 75.9 |
| 35–39 | 34,131 | 20,462 | 60.0 | 32,691 | 20,582 | 63.0 | 32,125 | 21,619 | 67.3 | 30,748 | 22,646 | 73.7 | 29,265 | 22,817 | 78.0 |
| 40–44 | 49,480 | 30,936 | 62.5 | 46,859 | 30,942 | 66.0 | 44,377 | 31,204 | 70.3 | 39,853 | 30,267 | 75.9 | 35,779 | 28,597 | 79.9 |
| 45–49 | 58,975 | 38,295 | 64.9 | 58,314 | 39,962 | 68.5 | 57,107 | 41,622 | 72.9 | 51,928 | 40,707 | 78.4 | 46,757 | 38,386 | 82.1 |
| 50–54 | 45,519 | 30,170 | 66.3 | 47,841 | 33,591 | 70.2 | 50,094 | 37,599 | 75.1 | 49,757 | 39,940 | 80.3 | 49,520 | 41,611 | 84.0 |
| 55–59 | 27,507 | 18,644 | 67.8 | 30,171 | 21,729 | 72.0 | 32,796 | 25,245 | 77.0 | 33,065 | 27,089 | 81.9 | 33,989 | 29,140 | 85.7 |
| 60–64 | 13,216 | 9,205 | 69.7 | 15,026 | 11,095 | 73.8 | 16,791 | 13,182 | 78.5 | 17,580 | 14,654 | 83.4 | 19,083 | 16,622 | 87.1 |
| ≥65 | 8,055 | 5,691 | 70.7 | 8,853 | 6,609 | 74.7 | 10,050 | 8,109 | 80.7 | 10,684 | 9,048 | 84.7 | 12,033 | 10,641 | 88.4 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **RACE/ETHNICITY** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| American Indian/Alaska Native | 1,426 | 926 | 64.9 | 1,334 | 910 | 68.2 | 1,338 | 968 | 72.3 | 1,389 | 1,031 | 74.2 | 1,222 | 1,007 | 82.4 |
| Asian | 3,283 | 2,127 | 64.8 | 3,489 | 2,357 | 67.6 | 3,883 | 2,812 | 72.4 | 3,745 | 2,939 | 78.5 | 3,563 | 2,973 | 83.4 |
| Black/African American | 142,549 | 81,081 | 56.9 | 146,376 | 89,621 | 61.2 | 147,607 | 97,447 | 66.0 | 143,006 | 103,348 | 72.3 | 136,106 | 105,301 | 77.4 |
| Hispanic/Latino | 69,247 | 43,490 | 62.8 | 69,655 | 47,101 | 67.6 | 73,654 | 53,572 | 72.7 | 73,434 | 57,419 | 78.2 | 71,726 | 59,238 | 82.6 |
| Native Hawaiian/Pacific Islander | 613 | 355 | 57.9 | 689 | 468 | 67.9 | 563 | 367 | 65.2 | 498 | 338 | 67.9 | 423 | 319 | 75.4 |
| White | 82,120 | 56,123 | 68.3 | 81,442 | 57,284 | 70.3 | 82,420 | 61,371 | 74.5 | 77,653 | 62,245 | 80.2 | 73,110 | 61,231 | 83.8 |
| Multiple races | 3,103 | 2,073 | 66.8 | 3,639 | 2,400 | 66.0 | 4,174 | 2,993 | 71.7 | 4,822 | 3,762 | 78.0 | 5,415 | 4,525 | 83.6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **GENDER** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Male | 213,843 | 133,320 | 62.3 | 218,043 | 143,322 | 65.7 | 225,121 | 157,962 | 70.2 | 217,285 | 165,260 | 76.1 | 206,820 | 166,910 | 80.7 |
| Female | 91,302 | 53,803 | 58.9 | 92,015 | 58,653 | 63.7 | 90,579 | 62,303 | 68.8 | 87,744 | 65,827 | 75.0 | 84,224 | 67,193 | 79.8 |
| Transgender | 2,260 | 1,252 | 55.4 | 2,531 | 1,521 | 60.1 | 2,787 | 1,849 | 66.3 | 2,719 | 1,961 | 72.1 | 2,827 | 2,081 | 73.6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **TRANSMISSION RISK** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Male client** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Male-to-male  sexual contact | 114,410 | 73,970 | 64.7 | 117,852 | 80,107 | 68.0 | 126,078 | 90,305 | 71.6 | 125,023 | 96,849 | 77.5 | 121,025 | 99,432 | 82.2 |
| Injection drug use | 17,104 | 10,944 | 64.0 | 16,533 | 11,145 | 67.4 | 15,364 | 11,288 | 73.5 | 15,282 | 12,055 | 78.9 | 13,529 | 11,005 | 81.3 |
| Male-to-male  sexual contact  and injection drug  use | 6,819 | 4,752 | 69.7 | 6,703 | 4,698 | 70.1 | 6,849 | 4,969 | 72.6 | 6,053 | 4,645 | 76.7 | 6,196 | 4,937 | 79.7 |
| Heterosexual  contact | 47,183 | 29,400 | 62.3 | 49,352 | 32,190 | 65.2 | 50,884 | 35,826 | 70.4 | 49,849 | 37,767 | 75.8 | 48,956 | 39,925 | 81.6 |
| Perinatal infection | 3,811 | 1,843 | 48.4 | 3,895 | 1,839 | 47.2 | 3,570 | 1,848 | 51.8 | 3,394 | 1,867 | 55.0 | 3,400 | 1,871 | 55.0 |
| Other | 1,228 | 889 | 72.4 | 1,212 | 883 | 72.9 | 1,282 | 993 | 77.5 | 1,363 | 1,141 | 83.7 | 1,166 | 981 | 84.1 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Female client** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Injection drug use | 9,100 | 5,667 | 62.3 | 8,911 | 5,926 | 66.5 | 8,091 | 5,822 | 72.0 | 8,206 | 6,299 | 76.8 | 7,254 | 5,838 | 80.5 |
| Heterosexual  contact | 66,507 | 40,402 | 60.7 | 68,474 | 44,842 | 65.5 | 69,050 | 48,516 | 70.3 | 68,171 | 52,329 | 76.8 | 66,736 | 54,544 | 81.7 |
| Perinatal infection | 4,317 | 2,092 | 48.5 | 4,544 | 2,183 | 48.0 | 4,149 | 2,199 | 53.0 | 3,982 | 2,276 | 57.2 | 4,036 | 2,399 | 59.4 |
| Other | 874 | 590 | 67.5 | 861 | 619 | 71.9 | 922 | 695 | 75.4 | 1,033 | 856 | 82.9 | 924 | 766 | 82.9 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Transgender client** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sexual contact | 1,833 | 1,055 | 57.6 | 2,014 | 1,264 | 62.8 | 2,231 | 1,505 | 67.5 | 2,264 | 1,662 | 73.4 | 2,372 | 1,788 | 75.4 |
| Injection drug use | 38 | 21 | 55.3 | 31 | 18 | 58.1 | 34 | 28 | 82.4 | 32 | 25 | 78.1 | 29 | 20 | 69.0 |
| Sexual contact and  injection drug use | 142 | 80 | 56.3 | 154 | 97 | 63.0 | 156 | 110 | 70.5 | 128 | 89 | 69.5 | 132 | 95 | 72.0 |
| Perinatal infection | 5 | 2 | 40.0 | 5 | 1 | 20.0 | 2 | 2 | 100.0 | 3 | 2 | 66.7 | 9 | 5 | 55.6 |
| Other | 6 | 4 | 66.7 | 5 | 2 | 40.0 | 8 | 6 | 75.0 | 9 | 8 | 88.9 | 8 | 6 | 75.0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **HEALTH CARE COVERAGE** | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Private only | 34,716 | 22,723 | 65.5 | 36,957 | 24,069 | 65.1 | 39,410 | 28,066 | 71.2 | 36,580 | 28,738 | 78.6 | ─ | ─ | ─ |
| Medicare only | 22,927 | 15,932 | 69.5 | 24,039 | 17,440 | 72.5 | 23,286 | 18,125 | 77.8 | 22,662 | 18,657 | 82.3 | ─ | ─ | ─ |
| Medicaid only | 71,446 | 40,897 | 57.2 | 74,189 | 47,111 | 63.5 | 70,610 | 48,682 | 68.9 | 67,969 | 50,388 | 74.1 | ─ | ─ | ─ |
| Other public | 21,824 | 14,813 | 67.9 | 20,355 | 14,736 | 72.4 | 27,352 | 21,562 | 78.8 | 26,618 | 21,298 | 80.0 | ─ | ─ | ─ |
| Other private | 11,152 | 7,965 | 71.4 | 9,575 | 7,250 | 75.7 | 5,874 | 4,168 | 71.0 | 3,615 | 2,769 | 76.6 | ─ | ─ | ─ |
| No coverage | 83,393 | 46,794 | 56.1 | 97,092 | 58,807 | 60.6 | 100,436 | 63,833 | 63.6 | 98,812 | 71,268 | 72.1 | ─ | ─ | ─ |
| Multiple coverages | 33,668 | 23,776 | 70.6 | 35,820 | 25,811 | 72.1 | 42,407 | 32,489 | 76.6 | 44,070 | 35,703 | 81.0 | ─ | ─ | ─ |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Private employer | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 17,859 | 15,736 | 88.1 |
| Private individual | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 15,475 | 12,931 | 83.6 |
| Medicare | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 25,792 | 22,177 | 86.0 |
| Medicaid | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 91,055 | 72,158 | 79.2 |
| Medicare and  Medicaid | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 18,994 | 16,401 | 86.3 |
| Veterans  Administration | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 435 | 370 | 85.1 |
| Indian Health  Service | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 66 | 56 | 84.8 |
| Other plan | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 11,558 | 9,673 | 83.7 |
| No coverage | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 84,961 | 65,192 | 76.7 |
| Multiple coverages | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 21,892 | 17,663 | 80.7 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **PROVIDER TYPE** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hospital/university-  based clinic | 141,019 | 90,394 | 64.1 | 148,597 | 100,305 | 67.5 | 148,527 | 109,569 | 73.8 | 141,018 | 110,731 | 78.5 | 138,848 | 114,396 | 82.4 |
| Community based  organization | 110,286 | 70,040 | 63.5 | 108,363 | 75,524 | 69.7 | 111,575 | 82,579 | 74.0 | 113,335 | 89,924 | 79.3 | 100,869 | 83,579 | 82.9 |
| Health department | 52,478 | 25,590 | 48.8 | 52,716 | 25,810 | 49.0 | 56,112 | 28,186 | 50.2 | 53,701 | 33,195 | 61.8 | 55,687 | 39,882 | 71.6 |
| Other | 14,574 | 10,096 | 69.3 | 12,285 | 8,692 | 70.8 | 11,687 | 8,684 | 74.3 | 12,327 | 9,686 | 78.6 | 12,789 | 10,762 | 84.2 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **NHAS\* POPULATIONS** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Black women | 55,658 | 31,512 | 56.6 | 56,246 | 34,676 | 61.7 | 54,998 | 36,681 | 66.7 | 52,819 | 38,717 | 73.3 | 50,253 | 39,284 | 78.2 |
| Black men | 85,694 | 48,980 | 57.2 | 88,888 | 54,261 | 61.0 | 91,161 | 59,874 | 65.7 | 88,767 | 63,667 | 71.7 | 84,247 | 64,938 | 77.1 |
| Hispanic women | 17,982 | 11,072 | 61.6 | 18,208 | 12,285 | 67.5 | 18,200 | 13,278 | 73.0 | 18,179 | 14,234 | 78.3 | 17,839 | 14,746 | 82.7 |
| Hispanic men | 50,539 | 31,970 | 63.3 | 50,640 | 34,277 | 67.7 | 54,564 | 39,634 | 72.6 | 54,378 | 42,506 | 78.2 | 52,964 | 43,759 | 82.6 |
| Youth (13-24 years) | 3,575 | 1,645 | 46.0 | 3,590 | 1,775 | 49.4 | 3,659 | 1,950 | 53.3 | 3,455 | 2,215 | 64.1 | 2,601 | 1,875 | 72.1 |
| Transgender  women | 1,679 | 985 | 58.7 | 2,028 | 1,290 | 63.6 | 2,285 | 1,607 | 70.3 | 2,264 | 1,698 | 75.0 | 2,386 | 1,814 | 76.0 |

\*National HIV/AIDS Strategy

*Data source*

The data source for this analysis is the Ryan White HIV/AIDS Program Services Report (RSR). The Ryan White HIV/AIDS Program supports a comprehensive system of care that ensures ongoing access to high quality HIV care, treatment, and support services. The RSR dataset is the HRSA HIV/AIDS Bureau’s primary source of annual, provider- and client-level data collected from more than 2,000 funded grant recipients and subrecipients. Since 2010, RSR data have been used to assess the numbers and types of clients receiving services and their HIV-related outcomes. The analysis includes data reported to the RSR for clients living with HIV served by the Ryan White HIV/AIDS Program during calendar years 2010 through 2014. The data are inclusive of all Ryan White HIV/AIDS Program providers delivering outpatient ambulatory medical care to clients living with HIV.

Summary of measured entities (providers) and patients, by year

|  |  |  |
| --- | --- | --- |
| Year | Providers (N) | Patients (N) |
| 2010 | 846 | 324,455 |
| 2011 | 811 | 327,744 |
| 2012 | 816 | 335,408 |
| 2013 | 823 | 327,618 |
| 2014 | 813 | 316,087 |

1b.5. If no or limited data on disparities from the measure as specified is reported in 1b.4, then provide a summary of data from the literature that addresses disparities in care on the specific focus of measurement. N/A

Scientific Acceptability

Testing Attachment

2. Attach measure testing form (Click to here to download the [Measure Testing Form Template](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/NQF_testing_attachment_FINAL_2016.aspx) OR the Composite Measure Testing Form.)

2.1. For maintenance of endorsement:

Reliability testing: If testing of reliability of the measure score was not presented in prior submission(s), has reliability testing of the measure score been conducted? If yes, please provide results in the Testing attachment. (Do not remove prior testing information – include date of new information in red.)

Yes, information in the attached testing form is all new.

2.2. For maintenance of endorsement:

Has additional empirical validity testing of the measure score been conducted?

No

2.3. For maintenance of endorsement:

No ‐ This measure is not risk‐adjusted.

Feasibility

3a.1. How are the data elements needed to compute measure scores generated? (Check all that apply)

Data used in the measure are:

Generated "or collected" by and used by healthcare personnel during the provision of care (e.g., blood pressure, lab value, diagnosis, "depression score")

Abstracted from a record by someone other than person obtaining original information (e.g., chart abstraction for quality measure or registry)

Electronic Sources ([Measure evaluation criterion 3b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#3b))

3b.1. To what extent are the specified data elements available electronically in defined fields ( *i.e., data* *elements that are needed to compute the performance measure score are in defined, computer‐readable fields*)Update this field for maintenance of endorsement.

ALL data elements are in defined fields in electronic health records (EHRs)

3b.2. If ALL the data elements needed to compute the performance measure score are not from electronic sources, specify a credible, near‐term path to electronic capture, OR provide a rationale for using other than electronic sources. For maintenance of endorsement, if this measure is not an eMeasure (eCQM), please describe any efforts to develop an eMeasure (eCQM).

For this measure, we are also presenting an e-measure.

3b.3. If this is an eMeasure, provide a summary of the feasibility assessment in an attached file or make available at a measure‐specific URL. Please also complete and attach the NQF Feasibility Score Card. N/A

Data Collection Strategy ([Measure evaluation criterion 3c](http://nqf.qualityforum.dev.win.dotnet.panth.com/#3c))

3c.1. Required for maintenance of endorsement. Describe difficulties (as a result of testing and/or operational use of the measure) regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues.

Data collection and availability: The data used for testing and operational use of this measure are readily available within patient health records and provided annually to the Ryan White HIV/AIDS Program through the reporting of the Ryan White Service Report (approved by the Office of Management and Budget 0915-0323).

Missing data: A full analysis of missing data is provided in this submission.

Time and frequency of data collection: As noted previously, all variables to calculate this measure are contained in a patient health record in a structured field. These data are routinely collected in the provision of care to people living with HIV. Because the availability of data, sampling is not performed.

Patient confidentiality: The data used in the testing of this measure are deidentified/striped of personally identifiable information prior to submitting.

3c.2. Describe any fees, licensing, or other requirements to use any aspect of the measure as specified (e.g., value/code set, risk model, programming code, algorithm)?

No fees, licensing, or other requirements to use any aspect of the measure.

Usability and Use

4.1. Current and Planned Use *(check all the current and planned uses; for any current uses that are checked,* *provide a program name and URL for the specific program)*

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Intended Use | | | Specific | | | Current | | For current use, provide Program Name and URL |  | |
|  |  | | |  | | |  | |  |  | |
|  | |  |  | |  |  | | | | |
|  | |  | Plan for | |  | Use | |  | | |
|  | |  | Use | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | a. Public Reporting | X | |  | X | | Ryan White HIV/AIDS Program and Medicaid Adult Core Set | | |
|  | |  |  | |  |  | |  | | |
|  | | b. Public Health/Disease Surveillance |  | |  | X | | National HIV/AIDS Strategy | | |
|  | |  |  | |  |  | |  | | |
|  | | c. Payment Program | X | |  | X | | Physician Quality Report System and Merit-Based Incentive Payment System | | |
|  | |  |  | |  |  | |  | | |
|  | | d. Regulatory and Accreditation Programs |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | e. Professional Certification or Recognition |  | |  |  | |  | | |
|  | | Program |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | f. Quality Improvement with Benchmarking |  | |  |  | |  | | |
|  | | (external benchmarking to multiple |  | |  |  | | National HIV/AIDS Strategy | | |
|  | | organizations) |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | g. Quality Improvement (Internal to the specific |  | |  |  | | Ryan White HIV/AIDS Program | | |
|  | | organization) |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |



Accountability/Transparency ([measure evaluation criterion 4a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#4a))

4a.1. For each CURRENT use, checked above (update for maintenance of endorsement), provide:

Name of program and sponsor Purpose; Geographic area and number and percentage of accountable entities and patients included Level of measurement and setting

Ryan White HIV/AIDS Program

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Approximately 600 Ryan White HIV/AIDS Program grant recipients and their providers

Patients: Approximately 316,000 patients

Medicaid Adult Core Set

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: State Medicaid programs

Patients: Unknown

Physician Quality Report System and Value Based Modifier

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Physicians and practitioners

Patients: Unknown

Merit-Based Incentive Payment System

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Physicians, Physician Assistant, Nurse Practitioner, and Clinical Nurse Specialist

Patients: Unknown

National HIV/AIDS Strategy

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Federal agencies and service providers

Patients: All people living with HIV in the United States

4a.2. If not currently publicly reported OR used in at least one other accountability application (e.g., payment program, certification, licensing) what are the reasons? ( *e.g., Do policies or actions of the* *developer/steward or accountable entities restrict access to performance results or impede implementation?*) N/A

4a.3. If not currently publicly reported OR used in at least one other accountability application, provide a credible plan for implementation within the expected timeframes ‐‐ any accountability application within 3 years and publicly reported within 6 years of initial endorsement. N/A

Improvement ([measure evaluation criterion 4b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#4b))

4b. Refer to data provided in 1b but do not repeat here. Discuss any progress on improvement (trends in performance results, number and percentage of people receiving high‐quality healthcare; Geographic area and number and percentage of accountable entities and patients included.)

HIV viral suppression has been improving in the United States since the first release of publically available data. The Ryan White HIV/AIDS Program served more than 300,000 unduplicated patients annually between 2010-2014 across 2,000+ grant recipients and subrecipients. The Ryan White HIV/AIDS Program has experienced a 20-point increase in viral suppression from 61.8% in 2010 to 80.3% in 2014. Viral suppression has increased across all demographic groups and subpopulations.

Unexpected findings ([measure evaluation criterion 4c](http://nqf.qualityforum.dev.win.dotnet.panth.com/#4c))

4c.1. Please explain any unexpected findings (positive or negative) during implementation of this measure including unintended impacts on patients.

The adoption and use of this measure has continued to spread since the initial development of this measure. This measure has been adopted by Centers for Medicare and Medicaid measurement programs, Department of Health and Human Service Secretary as a one of the core HIV indicators, countless outpatient/ambulatory care settings, and health departments. National learning collaborates have used this measure to focus the improvement efforts of grant recipients and subrecipients. Additionally, viral suppression is the final and goal of the five stages of the HIV care continuum. This measure has become the standard when measuring viral suppression.

4c.2. Please explain any unexpected benefits from implementation of this measure.

N/A

4d1.1. Describe how performance results, data, and assistance with interpretation have been provided to those being measured or other users during development or implementation.

Starting in 2015, Health Resources and Services Administration began releasing December 1st – World AIDS Day – an annual data report (Ryan White HIV/AIDS Program Annual Client-Level Data Report) that contains data similar to those presenting in the report. Building upon the success of the state profiles (<http://hab.hrsa.gov/stateprofiles/>), Health Resources and Services Administration worked diligently to release the annual data report in the same year it was collected (collected in April and released in December of the same year). The report is publically available on the Health Resources and Services Administration website (http://hab.hrsa.gov/data/data-reports) and is released via an accompanying webinar (recorded and archived). A supplemental report exploring data for the eligible metropolitan areas and transitional grant areas and youth/young adults has been released as well as slides sets for fact sheets by program and population, special populations (http://hab.hrsa.gov/publications/hivaids-bureau-fact-sheets), and infographics (contained in fact sheets). Additionally, grant recipient level reports are prepared and disseminated to all Ryan White HIV/AIDS Program grant recipients.

HRSA is releasing a quality module where grant recipients can voluntarily report numerator, denominator, and performance scores for a portfolio of measures. Grant recipients will be able to benchmark their performance based on a number of patient demographic and organizational factors. This measure will be included in the measure portfolio.

4d1.2. Describe the process(es) involved, including when/how often results were provided, what data were provided, what educational/explanatory efforts were made, etc. .

Starting in 2015, Health Resources and Services Administration began releasing December 1st – World AIDS Day – an annual data report (Ryan White HIV/AIDS Program Annual Client-Level Data Report) that contains data similar to those presenting in the report. Building upon the success of the state profiles (<http://hab.hrsa.gov/stateprofiles/>), Health Resources and Services Administration worked diligently to release the annual data report in the same year it was collected (collected in April and released in December of the same year). The report is publically available on the Health Resources and Services Administration website (http://hab.hrsa.gov/data/data-reports) and is released via an accompanying webinar (recorded and archived). A supplemental report exploring data for the eligible metropolitan areas and transitional grant areas and youth/young adults has been released as well as slides sets for fact sheets by program and population, special populations (http://hab.hrsa.gov/publications/hivaids-bureau-fact-sheets), and infographics (contained in fact sheets). Additionally, grant recipient level reports are prepared and disseminated to all Ryan White HIV/AIDS Program grant recipients.

4d2.1. Summarize the feedback on measure performance and implementation from the measured entities and others described in 4d.1.

Antidotal feedback has been received from Ryan White HIV/AIDS Program grant recipients and subrecipients regarding the feasibility and usefulness of the data presented in the Ryan White HIV/AIDS Program Annual Client-Level Data Report. Significant feedback has been provided about the timeliness and expansions of the data release. Grant recipient report using the data for benchmarking their program, setting goals/targets, and gaining a fuller understanding of all aspects of the Ryan White HIV/AIDS Program (i.e. other regions of the country). Grant recipients and subrecipients have also requested additional analyses. Health Resources and Services Administration responded with supplemental reports (Ryan White HIV/AIDS Program Supplemental Client-Level Data Report, Eligible Metropolitan Areas and Transitional Grant Areas; special population reports); slide decks for the overall client population and special populations; grant recipient reports; and infographics – all of which will be updated and released annually. Health Resources and Services Administration plans to release additional analyses and special reports this year based on feedback from Ryan White HIV/AIDS Program grant recipients and subrecipients.

4d2.2. Summarize the feedback obtained from those being measured.

See 4d2.2

4d2.3. Summarize the feedback obtained from other users.

Ryan White HIV/AIDS Program national partners (national organizations that represent grant recipients, subrecipients, and patients) has provided antidotal feedback regarding the timeliness, feasibility, and usability of the release of the Ryan White HIV/AIDS Program Annual Client-Level Data Report, supplemental reports, slide decks, fact sheets, and infographics. The national partners encourage the continued release of the data in all its formats.

4d.3. Describe how the feedback described in 4d.2 has been considered when developing or revising the measure specifications or implementation, including whether the measure was modified and why or why not

During the initial development of the measure, formal feedback was gathered. The measures were modified during the development phase and have not been modified since. A concerted effort was made to develop a measure that would likely stand the test of time from a scientific, clinical, and patient perspective. On an annual basis, the measure is review for clinical relevance, change in scientific acceptability, and consistency with guidelines. This measure has not been modified as a result of the annual reviews. Additionally, this measure is used by a number of measurement programs and strategies. Each of those programs require a separate annual review. No modifications have been made for those programs.

Related and Competing Measures

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure.

Relation to Other NQF‐endorsed® Measures ([Measure evaluation criterion 5](http://nqf.qualityforum.dev.win.dotnet.panth.com/#5))

5. Are there related measures (conceptually, either same measure focus or target population) or competing measures (conceptually both the same measure focus and same target population)? If yes, list the NQF # and title of all related and/or competing measures. (Can search and select measures.)

0405 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis

0409 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis

2079 HIV Medical Visit Frequency

2080 Gap in HIV Medical Visits

2083 Prescription of HIV Antiretroviral Therapy

3211 Prescription of HIV Antiretroviral Therapy

3210 HIV Viral Suppression

3010 HIV Medical Visit Frequency

Harmonization of Related Measures ([Measure evaluation criterion 5a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#5a))

5a.1. If this measure conceptually addresses EITHER the same measure focus OR the same target population as NQF‐endorsed measure(s):Are the measure specifications harmonized to the extent possible?

Yes

5a.2. If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden. N/A

Competing Measure(s) ([Measure evaluation criterion 5b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#5b))

5b.1. If this measure conceptually addresses both the same measure focus and the same target population as NQF‐ endorsed measure(s):

Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible.)

This measure does not have a competing measure.